Rhythm Pharmaceuticals, Inc.
RYTM
$93.72
$2.412.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.99% | 11.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.99% | 11.61% | |||
| Cost of Revenue | 49.04% | -12.68% | |||
| Gross Profit | 0.96% | 14.52% | |||
| SG&A Expenses | 10.63% | 9.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.82% | 0.35% | |||
| Operating Income | -11.26% | 10.62% | |||
| Income Before Tax | -15.90% | 9.96% | |||
| Income Tax Expenses | 1,858.06% | -127.93% | |||
| Earnings from Continuing Operations | -17.12% | 10.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.12% | 10.21% | |||
| EBIT | -11.26% | 10.62% | |||
| EBITDA | -11.37% | 10.62% | |||
| EPS Basic | -14.31% | 10.85% | |||
| Normalized Basic EPS | -14.05% | 10.80% | |||
| EPS Diluted | -14.31% | 10.85% | |||
| Normalized Diluted EPS | -14.05% | 10.80% | |||
| Average Basic Shares Outstanding | 1.64% | 0.93% | |||
| Average Diluted Shares Outstanding | 1.64% | 0.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||